PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: A molecular shield to evade immune system?

PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: A molecular shield to evade immune system?

The programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) pathway has emerged as a critical inhibitory pathway regulating T-cell response in non-small-cell lung cancer (NSCLC), and the development of PD-1/PD-L1 inhibitors has changed the landscape of NSCLC therapy. Nevertheless, the high degree of no...

Full description

Bibliographic Details
Main Authors: Cristina Raimondi, Guido Carpino, Chiara Nicolazzo, Angela Gradilone, Walter Gianni, Alain Gelibter, Eugenio Gaudio, Enrico Cortesi, Paola Gazzaniga
Format: Article
Language:English
Published: Taylor & Francis Group 2017-12-01
Series:OncoImmunology
Subjects:
circulating tumor cells
epithelial mesenchymal transition
lung cancer
pd-l1
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1315488

Internet

http://dx.doi.org/10.1080/2162402X.2017.1315488

Similar Items